CLINICAL RELEVANCE OF ENDOTHELIUM-DERIVED RELAXING FACTOR (EDRF)

被引:31
作者
BASSENGE, E
机构
[1] Department of Applied Physiology, University of Freiburg
关键词
ENDOTHELIUM-DERIVED RELAXING FACTOR; NITRIC OXIDE;
D O I
10.1111/j.1365-2125.1992.tb04147.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 In addition to metabolic and neurohumoral factors endothelium-derived autacoids like the nitric oxide radical NO and prostacyclin are effective regulators of vascular tone and thus tissue perfusion. NO is produced in endothelial cells from L-arginine by a Ca2+/calmodulin-dependent enzyme NO synthase. In addition, the NO radical is ultimately cleaved from all nitrovasodilators and resembles their vasoactive and antiaggregatory principle, which is used under pathological conditions as substitution therapy for impaired endothelial function and autacoid production. Impaired endothelium-dependent vasomotor control has been documented in hypercholesterolaemia, atheromatosis, diabetes, hypertension, and in reperfusion damage. L-arginine supplementation is effective in a few instances.
引用
收藏
页码:S37 / S42
页数:6
相关论文
共 61 条
[1]   CARDIOPROTECTIVE ACTIONS OF HUMAN SUPEROXIDE-DISMUTASE IN 2 REPERFUSION MODELS OF MYOCARDIAL ISCHEMIA IN THE RAT [J].
AOKI, N ;
BITTERMAN, H ;
BREZINSKI, ME ;
LEFER, AM .
BRITISH JOURNAL OF PHARMACOLOGY, 1988, 95 (03) :735-740
[2]  
BASSENGE E, 1988, Cardiovascular Drugs and Therapy, V2, P27, DOI 10.1007/BF00054249
[3]   FLOW-DEPENDENT REGULATION OF CORONARY VASOMOTOR TONE [J].
BASSENGE, E .
EUROPEAN HEART JOURNAL, 1989, 10 :22-27
[4]  
Bassenge E, 1990, Rev Physiol Biochem Pharmacol, V116, P77
[5]  
BASSENGE E, 1991, BASIC RES CARDIOL, V86, P69
[6]  
BASSENGE E, 1989, Z KARDIOL, V78, P54
[7]  
BASSENGE E, 1992, FASEB J, V6, pA1212
[8]  
BASSENGE E, 1989, NITROGLYCERIN, V6, P49
[9]  
BOGLE RG, 1991, 2ND P INT M BIOL NIT
[10]   CAS-936, A NOVEL SYDNONIMINE WITH DIRECT VASODILATING AND NITRIC OXIDE-DONATING PROPERTIES - EFFECTS ON ISOLATED BLOOD-VESSELS [J].
BOHN, H ;
BEYERLE, R ;
MARTORANA, PA ;
SCHONAFINGER, K .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 18 (04) :522-527